RVNC News and Press, Revance Therapeutics Inc. From 11/01/18

Revance Therapeutics (NASDAQ: RVNC ): Q3 GAAP EPS of -$0.91 beats by $0.12 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Chief Financial Officer Toby Schilke and Interim Head of Commercial - Aesthetics & Therapeutics Dustin Sjuts to assume roles on November 5 - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic a...

-Conference Call Scheduled for Thursday, November 1, 2018 at 4:30pm ET- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release second quar...

NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Materion Corporation (NYSE:MTRN), Iridium Communications Inc (NASDAQ:I...

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that it has strengthened its leadership team with the appointment of Tobin C. Schilke as chief financial officer, effective N...